Partner, Patent Attorney
Life Sciences


Thomas works primarily in the biopharma sector, mainly with big pharma companies undertaking drug discovery and development. He advises on all stages of a drug’s lifecycle, from initial discovery through clinical trials to regulatory approval. Working closely with in-house IP teams and scientists, he has extensive experience of the prosecution and European opposition and appeal procedures as well as SPCs. Thomas was involved in litigation and/or opposition proceedings concerning dasatinib, nivolumab, ipilimumab, eptinezumab, abatacept, belatacept, crenezumab, etanercept, calcipotriol, levofloxacin, and others.

Areas of Expertise

Immunology and immuno-oncology Therapeutic antibodies Fusion proteins Human blood plasma products Iron carbohydrate complexes Production and formulation of biologics Special drug forms, e.g., polymorphs and enantiomers Combination therapies


Thomas works mainly with biopharma companies including large US and European multinationals, SME's and small biotechs.


Thomas has a double Master’s degree in chemistry and biology from Ruhr-Universität Bochum, Germany, and a PhD from Université Louis Pasteur Strasbourg, France.

He qualified as German and European Patent Attorney in 1999. He has practiced at a German patent law firm before joining Mewburn Ellis in 2020.